Dietitians Australia has provided a submission to the Pharmaceutial Benefits Advisory Committee on 1) equitable access to glucagon-like peptide-1 (GLP-1) receptor agonist medicines through the Pharmaceutical Benefits Scheme for the treatment of obesity; and 2) SEMAGLUTIDE - Wegovy: Established cardiovascular disease with obesity. We call on the Government to: 1. Require referral to an APD before and on prescription of GLP-1 RA medicines for any therapeutic purpose. 2. Ensure consumer access to APDs before, during and after using GLP-1RA medicines.

To read more, download our full submission.